Download PDF
TumorDiagnostik & Therapie 2014; 35(4): 204-211
DOI: 10.1055/s-0034-1369139
Schwerpunkt: Nierenzellkarzinom
Georg Thieme Verlag KG Stuttgart · New York

Übersicht – Leitliniengerechte Therapie des metastasierten Nierenzellkarzinoms

C. Doehn
,
P. J. Goebell
,
F. Overkamp
,
M. Staehler
Further Information

Publication History

Publication Date:
25 June 2014 (online)

Also available at
    Permissions and Reprints

Das therapeutische Vorgehen beim weitgehend zytostatikaresistenten metastasierten Nierenzellkarzinom (mRCC) war lange schwierig. Fortschritte wurden erst durch den vertieften Einblick in die molekulare Pathogenese möglich. Die Blockade der Neoangiogenese als treibender Kraft bei der Proliferation dieses Tumors ist heute durch mehrere Wirkstoffklassen wie Tyrosinkinase-Inhibitoren (TKI), monoklonale Anti-VEGF-Antikörper sowie mTOR-Inhibitoren möglich. Hilfe bei der mittlerweile komplexen Therapiewahl bieten aktuelle Leitlinien von EAU, DGHO und ESMO mit evidenzbasierten Empfehlungen zur Erst- und Zweitlinientherapie des mRCC [1],[2],[3]. Bei der Therapieentscheidung sollten der prognostische Risikoscore des jeweiligen Patienten, klinische Faktoren und eventuelle Vortherapien berücksichtigt werden.

 

  • Literatur

  • 1 Escudier B, Eisen T, Porta C et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 07) vii65-vii71
    CrossrefPubMedGoogle Scholar
  • 2 Ljungberg B, Bensalah K, Bex A et al. Guidelines on renal cell carcinoma. EAU 2013;
    PubMedGoogle Scholar
  • 3 (Hypernephrom) Onkopedia-Leitlinie Nierenzellkarzinom. Online verfügbar unter. http://www.dgho-onkopedia.de
    PubMedGoogle Scholar
  • 4 Coppin C, Porzsolt F, Autenrieth M et al. Immunotherapy for advanced renal cell cancer. Cochrane Collaboration. The Cochrane Library 2008; (4) CD001425 DOI: 10.1002/14651858.CD001425.pub2.
    PubMedGoogle Scholar
  • 5 Motzer RJ, Figlin RA, Hutson TE et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124
    CrossrefPubMedGoogle Scholar
  • 6 Motzer RJ, Hutson TE, Tomczyk P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cancer. J Clin Oncol 2009; 27: 3584-3590
    CrossrefPubMedGoogle Scholar
  • 7 Motzer RJ, Hutson TE, Olsen MR et al. Randomized phase II multicenter study of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal renal cell carcinoma. J Clin Oncol 2012; 30: 1371-1377
    CrossrefPubMedGoogle Scholar
  • 8 Négrier S, Gravis G, Pérol D et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase II trial. Lancet Oncol 2011; 12: 673-680
    CrossrefPubMedGoogle Scholar
  • 9 Motzer RJ, Hudson TE, Reeves J et al. Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal-cell carcinoma (mRCC): results of the COMPARZ trial. ESMO 2012; Abstr. LBA8
    PubMedGoogle Scholar
  • 10 Jonasch E, Corn P, Pagliaro LC et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010; 116: 57-65
    PubMedGoogle Scholar
  • 11 Procopio G, Verzoni E, Bracarda S et al. Sorafenib with interleukin-2 vs. sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer 2011; 104: 1256-1261
    CrossrefPubMedGoogle Scholar
  • 12 Rini B, Szczylik C, Tannir NM et al. AMG386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 2012; 118: 6152-6161
    CrossrefPubMedGoogle Scholar
  • 13 Hutson TE, Gallardo J, Lesovoj V et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma. J Clin Oncol 2013; 31 (Suppl. 06) Abstr. LBA348
    PubMedGoogle Scholar
  • 14 Motzer R, Nosov D, Eisen T et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. J Clin Oncol 2012; 30 (Suppl) Abstr. 4501
    PubMedGoogle Scholar
  • 15 Motzer R, Eisen T, Hutson TE et al. Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma. J Clin Oncol 2013; 31 (Suppl. 06) Abstr. 350
    PubMedGoogle Scholar
  • 16 Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renall cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116: 1272-1280
    CrossrefPubMedGoogle Scholar
  • 17 Sternberg CN, Davis ID, Mardiak J et al. ; Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068
    CrossrefPubMedGoogle Scholar
  • 18 Sternberg CN, Hawkins RE, Wagstaff J et al. A randomized, double-blind phase III study of pazopanib in patients with advanced and / or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013; 49: 1287-1296
    CrossrefPubMedGoogle Scholar
  • 19 Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon-alfa2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111
    CrossrefPubMedGoogle Scholar
  • 20 Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90 206. J Clin Oncol 2008; 26: 5422-5428
    CrossrefPubMedGoogle Scholar
  • 21 Escudier B, Bellmunt J, Négrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-2150
    CrossrefPubMedGoogle Scholar
  • 22 Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90 206. J Clin Oncol 2010; 28: 2137-2143
    CrossrefPubMedGoogle Scholar
  • 23 Rini B, Bellmunt J, Clancy J et al. Randomized phase IIIb trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: Results from INTORACT. ESMO 2012; Abstr. LBA1487
    PubMedGoogle Scholar
  • 24 Melichar B, Bracarda S, Matveev V et al. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann Oncol 2013; DOI: 10.1093/annonc/mdt228.
    PubMedGoogle Scholar
  • 25 Hudes G, Carducci M, Tomczyk P et al. Temsirolimus, interferon α, or both for advanced renal cell carcinoma. N Engl J Med 2007; 336: 2271-2281
    PubMedGoogle Scholar
  • 26 Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell carcinoma. N Engl J Med 2007; 356: 125-34
    CrossrefPubMedGoogle Scholar
  • 27 Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-3318
    CrossrefPubMedGoogle Scholar
  • 28 Rini B, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomized phase three trial. Lancet 2011; 378: 1931-1939
    CrossrefPubMedGoogle Scholar
  • 29 Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013; 14: 552-562
    CrossrefPubMedGoogle Scholar
  • 30 Hutson TE, Escudier B, Esteban E. Temsirolimus vs. sorafenib as second-line therapy in metastatic renal cell carcinoma: Results from the INTORSECT trial. Ann Oncol 2012; 23 (Suppl. 09) LBA22
    CrossrefPubMedGoogle Scholar
  • 31 Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456
    CrossrefPubMedGoogle Scholar
  • 32 Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cancer. Cancer 2010; 116: 4356-4365
    PubMedGoogle Scholar
  • 33 Motzer RJ, Bono P, Hudes GR et al. A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy.
    PubMedGoogle Scholar
  • 34 Michel MS, Vervenne W, Goebell PJ et al. Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced / metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): Safety interim analysis results. J Clin Oncol 2012; 30 (suppl) Abstr. 4539
    PubMedGoogle Scholar
  • 35 Gschwend J, Beeker A, de Santis M et al. Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-2 study). J Clin Oncol 2013; 31 (suppl) Abstr. TPS4591
    PubMedGoogle Scholar
  • 36 Motzer RJ, Barrios CH, Kim TM et al. Record-3: Phase III randomized trial comparing seqential first-line everolimus (EVE) and second-line sunitinib (SUN) verusus first-line SUN and second-line EVE in patients with metastatic renall cell carcinoma (mRCC). J Clin Oncol 2013; 31 (Suppl) Abstr. 4504
    PubMedGoogle Scholar